Register Login

Tenax Therapeutics Inc. (TENX)

Director Davidson Michael H. 🟢 acquired 222.5K shares (7 derivative) of TENAX THERAPEUTICS, INC. (TENX) at $3,200.00 ($1.6M) Transaction Date: Jan 09, 2026 | Filing ID: 000001

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 2:26 p.m.

    🔍 Davidson Michael H. (Director)

    Company: TENAX THERAPEUTICS, INC. (TENX)

    Report Date: 2026-01-09

    Transaction Summary:

    • Total transactions: 8
    • Derivative instruments: 7
    • Holdings reported: 7
    • Total shares acquired: 30,000
    • Total shares held: 255,389

    Detailed Transactions and Holdings:

    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-01-09 | Code: H | shares_owned_after: 2,881.00
    • Acquired 30,000 shares of Stock Option (right to buy) at $13.3 per share (Derivative)
      Date: 2026-01-09 | Code: A | Expires: 2036-01-09 | Exercise: 2027-01-09 | equity_swap_involved: 0 | shares_owned_after: 30,000.00 | transaction_form_type: 4
    • Holds 4 shares of Stock Option (right to buy) at $3200.0 per share (Derivative)
      Date: 2026-01-09 | Code: H | Expires: 2031-06-10 | Exercise: 2022-06-10 | shares_owned_after: 4.00
    • Holds 4 shares of Stock Option (right to buy) at $992.0 per share (Derivative)
      Date: 2026-01-09 | Code: H | Expires: 2032-06-09 | Exercise: 2023-06-09 | shares_owned_after: 4.00
    • Holds 100,000 shares of Stock Option (right to buy) at $5.94 per share (Derivative)
      Date: 2026-01-09 | Code: H | Expires: 2034-12-10 | Exercise: 2025-12-10 | shares_owned_after: 100,000.00
    • Holds 80,000 shares of Stock Option (right to buy) at $5.75 per share (Derivative)
      Date: 2026-01-09 | Code: H | Expires: 2035-07-01 | Exercise: 2026-07-01 | shares_owned_after: 80,000.00
    • Holds 47,500 shares of Pre-Funded Warrant at $0.01 per share (Derivative)
      Date: 2026-01-09 | Code: H | Exercise: 2024-08-08 | shares_owned_after: 47,500.00 | Footnotes: F1
    • Holds 25,000 shares of Warrant at $4.5 per share (Derivative)
      Date: 2026-01-09 | Code: H | Exercise: 2024-08-08 | shares_owned_after: 25,000.00 | Footnotes: F2

    Footnotes:

    • F1: The pre-funded warrant has no expiration date.
    • F2: The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.

Search

News categories